MEIP MEI Pharma Inc

Price (delayed)

$3.37

Market cap

$22.45M

P/E Ratio

1.13

Dividend/share

N/A

EPS

$2.97

Enterprise value

$29.31M

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in ...

Highlights
MEI Pharma's debt has decreased by 10% YoY and by 2.9% QoQ
MEIP's net income has surged by 164% year-on-year but it has dropped by 52% since the previous quarter
The EPS has soared by 163% YoY but it has plunged by 52% from the previous quarter

Key stats

What are the main financial stats of MEIP
Market
Shares outstanding
6.66M
Market cap
$22.45M
Enterprise value
$29.31M
Valuations
Price to earnings (P/E)
1.13
Price to book (P/B)
0.38
Price to sales (P/S)
0.31
EV/EBIT
1.48
EV/EBITDA
1.35
EV/Sales
0.4
Earnings
Revenue
$72.65M
EBIT
$19.84M
EBITDA
$21.69M
Free cash flow
-$53.03M
Per share
EPS
$2.97
Free cash flow per share
-$7.96
Book value per share
$8.93
Revenue per share
$10.9
TBVPS
$11.79
Balance sheet
Total assets
$78.54M
Total liabilities
$19.05M
Debt
$12.03M
Equity
$59.49M
Working capital
$58.13M
Liquidity
Debt to equity
0.2
Current ratio
8.23
Quick ratio
7.4
Net debt/EBITDA
0.32
Margins
EBITDA margin
29.9%
Gross margin
100%
Net margin
27.3%
Operating margin
21.9%
Efficiency
Return on assets
18.3%
Return on equity
39.7%
Return on invested capital
27.7%
Return on capital employed
28.1%
Return on sales
27.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MEIP stock price

How has the MEI Pharma stock price performed over time
Intraday
3.69%
1 week
3.69%
1 month
-12.01%
1 year
-29.94%
YTD
-41.9%
QTD
-15.75%

Financial performance

How have MEI Pharma's revenue and profit performed over time
Revenue
$72.65M
Gross profit
$72.65M
Operating income
$15.88M
Net income
$19.84M
Gross margin
100%
Net margin
27.3%
MEIP's net income has surged by 164% year-on-year but it has dropped by 52% since the previous quarter
MEI Pharma's net margin has surged by 155% YoY but it has decreased by 30% QoQ
The operating income has soared by 134% YoY but it has plunged by 57% from the previous quarter
The operating margin has soared by 129% YoY but it has contracted by 37% from the previous quarter

Growth

What is MEI Pharma's growth rate over time

Valuation

What is MEI Pharma stock price valuation
P/E
1.13
P/B
0.38
P/S
0.31
EV/EBIT
1.48
EV/EBITDA
1.35
EV/Sales
0.4
The EPS has soared by 163% YoY but it has plunged by 52% from the previous quarter
The stock's price to book (P/B) is 88% less than its 5-year quarterly average of 3.3 and 62% less than its last 4 quarters average of 1.0
The equity fell by 27% QoQ but it rose by 23% YoY
MEIP's P/S is 97% below its 5-year quarterly average of 11.2 and 48% below its last 4 quarters average of 0.6
MEIP's revenue is down by 31% QoQ but it is up by 16% YoY

Efficiency

How efficient is MEI Pharma business performance
The ROE has soared by 166% YoY but it has shrunk by 54% QoQ
The ROS has soared by 155% YoY but it has contracted by 30% from the previous quarter
MEI Pharma's ROIC has soared by 142% YoY but it has plunged by 62% from the previous quarter
MEIP's return on assets is down by 44% since the previous quarter

Dividends

What is MEIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MEIP.

Financial health

How did MEI Pharma financials performed over time
The total liabilities has plunged by 81% YoY and by 4.2% from the previous quarter
The total assets has declined by 47% year-on-year and by 22% since the previous quarter
MEI Pharma's debt is 80% lower than its equity
MEI Pharma's debt to equity has increased by 33% QoQ but it has decreased by 29% YoY
The equity fell by 27% QoQ but it rose by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.